VIPIVOTIDE TETRAXETAN
Oligometastatic Prostate Cancer (OMPC)
Novartis PharmaceuticalsSmall moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
513 Active assets in the Oligometastatic Prostate Cancer (OMPC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Avodart Bay State Clinical Trials, Inc. | Phase 4 | BBB |
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
PROPOFOL Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
Degarelix Bayer | Phase 4 | BBB |
AVOLVE Masonic Cancer Center, University of Minnesota | Phase 4 | BB |
View all 50 →
Same molecule, other indications
VIPIVOTIDE TETRAXETAN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →